$3396 | SAVE $599 | Single User
$6792 | SAVE $1,198 | Site License
$10187 | SAVE $1,798 | Enterprise License

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
[Published by Global Data]

Published by Global Data: 09 Dec 2015 | 17801 | In Stock

Introduction

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

Summary

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue, and is characterized by excessive fibrosis, vascular alterations, and the proliferation of antibodies against numerous cellular antigens. SSc mainly affects those ages 40-50 years, and occurs predominantly in women, with a female-to-male sex ratio of 4:1. There are two main forms of the disease: limited and diffuse cutaneous scleroderma (lSSc and dSSc, respectively). lSSc primarily affects the hands, arms, and face, whereas dSSc affects a vast area of the skin and involves one or more internal organs. Raynaud’s phenomenon (RP) develops in the majority of both forms of SSc. The primary cause of death in both lSSC and dSSc is involvement of the lungs.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of SSc for ages 18 years and older will increase from 131,129 cases in 2014 to 141,499 cases in 2024. GlobalData epidemiologists forecast that in 2024, the US will have the highest number of diagnosed prevalent cases of SSc, with 95,992 cases, accounting for 68% of cases in the 7MM. In the 7MM in 2014, the group age 50-59 years had the highest proportion of diagnosed prevalent cases of SSc at 25.51%. In 2014, the diagnosed prevalent cases of SSc in the 7MM were lower in men compared with women with 15.36% diagnosed prevalent cases in men and 84.64% diagnosed prevalent cases in women. Of all the diagnosed prevalent cases of SSc in the 7MM in 2014, more had experienced RP (126,151 cases) than a DU (67,099 cases). In each of the 7MM, approximately 95% of the diagnosed prevalent SSc cases had experienced RP. In all markets other than France, Germany, and Italy, 70.50% of the diagnosed prevalent cases of SSc were lSSc. In the 7MM in 2014, 18,395 of the diagnosed prevalent cases of dSSc had ILD, and 6,679 of the diagnosed prevalent cases of dSSc had kidney disease.

GlobalData epidemiologists utilized comprehensive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of SSc. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for the diagnosed prevalent cases of SSc. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of SSc across these markets.

Scope

- The Systemic Sclerosis (SSc) EpiCast Report provides an overview of the risk factors and global trends of SSc in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of SSc diagnosed prevalent cases in these markets, segmented by age, sex, presence of Raynaud’s phenomenon (RP), presence of digital ulcers (DUs), limited systemic sclerosis (ISSc), and diffuse systemic sclerosis (dSSc). The diagnosed prevalent cases of dSSc are further segmented into cases with pulmonary fibrosis (PF)/interstitial lung disease (ILD) and kidney disease.

- The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SSc EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global SSc market.

- Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.

- Identify the percentage of SSc diagnosed prevalent cases by disease type.

Table of Contents
for EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 5

    1.2 List of Figures 6

    2 Introduction 7

    2.1 Catalyst 7

    2.2 Related Reports 8

    2.3 Upcoming Reports 8

    3 Epidemiology 9

    3.1 Disease Background 9

    3.2 Risk Factors and Comorbidities 9

    3.3 Global Trends 12

    3.4 Forecast Methodology 14

    3.4.1 Sources Used 15

    3.4.2 Sources Not Used 30

    3.4.3 Forecast Assumptions and Methods 30

    3.5 Epidemiological Forecast for SSc (2014-2024) 43

    3.5.1 Diagnosed Prevalent Cases of SSc 43

    3.5.2 Age-Specific Diagnosed Prevalent Cases of SSc 44

    3.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc 47

    3.5.4 Age-Standardized Prevalence of SSc 48

    3.5.5 Diagnosed Prevalent Cases of SSc with RP and SSc with DU 49

    3.5.6 SSc Segmented into lSSc and dSSc 51

    3.5.7 Sex-Specific Diagnosed Prevalent Cases of lSSc 52

    3.5.8 Sex-Specific Diagnosed Prevalent Cases of dSSc 53

    3.5.9 Diagnosed Prevalent Cases of dSSc with ILD and Cases with Kidney Disease 54

    3.6 Discussion 56

    3.6.1 Epidemiological Forecast Insight 56

    3.6.2 Limitations of the Analysis 56

    3.6.3 Strengths of the Analysis 57

    4 Appendix 58

    4.1 Bibliography 58

    4.2 About the Authors 63

    4.2.1 Epidemiologists 63

    4.2.2 Reviewers 64

    4.2.3 Global Director of Therapy Analysis and Epidemiology 65

    4.2.4 Global Head of Healthcare 65

    4.3 About GlobalData 66

    4.4 About EpiCast 66

    4.5 Disclaimer 67

List Of Tables
in EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for SSc 11

Table 2: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc 15

Table 3: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with RP 16

Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with DU 17

Table 5: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc, Segmented by lSSc and dSSc 18

Table 6: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with ILD 19

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with Kidney Disease 20

Table 8: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Select Years, 2014-2024 43

Table 9: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, N (Row%), 2014 45

Table 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, N (Row %), 2014 47

Table 11: 7MM, Diagnosed Prevalent Cases of SSc with RP, and SSc with DU, Both Sexes, Age ≥18 Years, N (% of Diagnosed Prevalent SSc Cases), 2014 50

Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of lSSc, Age ≥18 Years, N (Row %), 2014 53

Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of dSSc, Ages ≥18 Years, N (Row %), 2014 54

Table 14: 7MM, Diagnosed Prevalent Cases of dSSc with ILD and dSSc with Kidney Disease, Both Sexes, Age ≥15 Years, N (% of Diagnosed Prevalent dSSc Cases), 2014 55

List Of Figures, Charts and Diagrams
in EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Case Flow Map of the Diagnosed Prevalent Cases of SSc 21

Figure 2: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Selected Years, 2014-2024 44

Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, 2014 46

Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, 2014 48

Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of SSc, 2014 49

Figure 6: 7MM, Diagnosed Prevalent Cases of SSc with RP and SSc with DU, Both Sexes, Age ≥18 Years, N, 2014 51

Figure 7: 7MM, Diagnosed Prevalent Cases of SSc Classified as lSSc and dSSc, Both Sexes, Age ≥18 Years, N, 2014 52

Additional Details

Publisher

Global Data

Publisher Information

Reference

17801 | GDHCER109-15

Number of Pages

68

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023SummaryC...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info
SAVE 15% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,396 (normally
USD $3,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...